🇺🇸 FDA
Pipeline program

HG204

HG20401

Unknown gene_therapy active

Quick answer

HG204 for MECP2 Duplication Syndrome is a Unknown program (gene_therapy) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
MECP2 Duplication Syndrome
Phase
Unknown
Modality
gene_therapy
Status
active

Clinical trials